Allarity Therapeutics (ALLR) Cash & Equivalents (2020 - 2026)

Allarity Therapeutics (ALLR) has 7 years of Cash & Equivalents data on file, last reported at $19.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 21.38% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (down 21.38% YoY) and the FY2025 annual result came in at $14.7 million, changed N/A from the prior year.
• Cash & Equivalents rose to $19.8 million in Q1 2026, from $14.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $25.2 million in Q1 2025 to a low of $166000.0 in Q4 2023.
• A 5-year average of $9.7 million and a median of $7.7 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 13751.43% — and 2023, when it sank 97.97%.
• Tracing ALLR's Cash & Equivalents over 5 years: stood at $2.0 million in 2022, then plunged by 91.82% to $166000.0 in 2023, then surged by 11022.29% to $18.5 million in 2024, then slipped by 20.45% to $14.7 million in 2025, then surged by 34.89% to $19.8 million in 2026.
• The last three Cash & Equivalents figures came in at $19.8 million (Q1 2026), $14.7 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.